Stifel analyst Rick Wise lowered the firm’s price target on Baxter (BAX) to $38 from $46 and keeps a Buy rating on the shares. Baxter delivered basically as-expected sales and better-than-expected EPS, but Q3 performance and the post-release call were “complicated on several fronts” due to late-Q3 hurricane-related challenges negatively impacting Baxter’s North Cove manufacturing facility, the analyst tells investors. The late-Q3 hurricanes clearly have had a meaningfully negative Q4 impact, with management providing both sales and EPS guidance below prior consensus estimates, but management conveyed “considerable optimism” that in 2025 the RemainCo business ex-Kidney remains on track to grow sales 4%-5% year-over-year operationally and reach 16.5% adjusted operating margins, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BAX:
- Baxter price target lowered to $45 from $46 at Evercore ISI
- Baxter price target lowered to $36 from $40 at Wells Fargo
- Baxter International Reports Resilient Q3 2024 Performance
- Nvidia trades on Dow for first time, Rivian reports downbeat Q3: Morning Buzz
- Baxter sees Q4 adjusted EPS 77c-81c, consensus 84c
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
